Personalised Cancer Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 1475
Special Issue Editor
Special Issue Information
Dear Colleagues,
Personalized mRNA cancer vaccines are a form of immunotherapy treatment that is currently being tested in clinical trials. They are tailored to each person's cancer and work by training the immune system to recognize, destroy, and prevent the spread of cancer cells. In recent years, there has been a renewed interest in personalized cancer vaccines, primarily due to the use of innovative technologies to identify neoantigens and novel vaccine delivery platforms. There is currently one therapeutic cancer vaccine, namely sipuleucel-T (Provenge); this is a dendritic cell-based vaccine utilized for the treatment of castration-resistant prostate cancer. Personalized immunotherapy offers a means of enhancing these therapies, with dendritic cells being pulsed with specific neoantigens for a personalized immunotherapy that matches neoantigens on the surface of cancer cells with those of the vaccine components in each patient. In addition, these cancer vaccines may be combined with other immunotherapies. mRNA- and DNA-based vaccines present an additional opportunity for cancer therapeutics, and modified viral and peptide vaccines are also being investigated. Next-generation sequencing and molecular profiling, in combination with the ability to computationally predict antigens and proteins, allows one to create cancer vaccines. In this Special Issue, novel cancer vaccines, adjuvants, and therapeutics will be examined, with regard to their regulation and treatment of disease. Cancer vaccines are coming.
Dr. Andrew L. Coveler
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- peptide vaccines
- mRNA vaccines
- DNA vaccines
- cancer vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
